Skip Navigation
NIH HHS News Release Logo
National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Thursday, July 24, 2008

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

NIAID MEDIA AVAILABILITY
NIAID Announces Revised Priorities for
HIV Vaccine Research

WHAT:

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is reshaping its research enterprise to broaden HIV vaccine discovery activities. Many of the initiatives have evolved from ideas and opinions recently expressed by scientists either at NIAID’s HIV Vaccine Summit on March 25 or in response to two Requests for Information that NIAID issued in April.

There is broad scientific consensus that more extensive vaccine discovery efforts involving research in the laboratory, with non-human primates (NHPs), and in the clinic could yield greater understanding of how a successful HIV vaccine might be designed. To that end, NIAID has received approval from its AIDS Research Advisory Committee to develop two major new initiatives to support individual investigator-initiated grants in HIV vaccine discovery and other tactics to interrupt HIV transmission. For information on these initiatives, visit Basic Vaccine Discovery and Highly Innovative Tactics to Interrupt Transmission of HIV.

NIAID has also initiated activities to expand NHP research in support of HIV vaccine discovery. First, NIAID is partnering with organizations at NIH and beyond to better track NHP research needs so supply can keep pace with demand. Second, the Institute is planning a workshop on November 12–13, 2008, to explore in detail NHP research needs and approaches and to help guide the design of a future initiative. Third, NIAID’s HIV Vaccine Trials Network (HVTN) will promote the exchange of HIV vaccine scientists, particularly new or young HIV vaccine researchers, between NHP laboratories and human clinics to strengthen the bridges between NHP and human research and to ensure more directly comparable results. In addition, NIAID is committed to attracting and retaining young investigators in the field of HIV vaccines by helping them obtain their first grants.

To accommodate this shift of effort and resources toward HIV vaccine discovery research, NIAID plans to reconsider the number of awards in its preclinical HIV vaccine development programs. The Institute also plans to work with the HVTN to ensure that its clinical research infrastructure is nimble, expandable and contractible as the number and size of clinical studies dictate.

ARTICLE: AS Fauci et al. HIV vaccine research: the way forward. Science DOI: 10.1126/science.1161000.
WHO: Anthony S. Fauci, M.D., the director of NIAID, and Margaret Johnston, Ph.D., the director of the Vaccine Research Program in NIAID’s Division of AIDS, are available to comment on this article.
CONTACT: To schedule interviews, contact the NIAID Office of Communications, 301-402-1663, niaidnews@niaid.nih.gov.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Last Updated July 24, 2008